(OCS) Oculis Holding Ordinary - Overview
Exchange: NASDAQ •
Country: Switzerland •
Currency: USD •
Type: Common Stock •
ISIN: CH1242303498
Stock: Topical Steroid, Biologic, Neuroprotective Agent
Total Rating 37
Risk 36
Buy Signal 0.24
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.7% |
| Relative Tail Risk | -26.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.71 |
| Alpha | 13.50 |
| Character TTM | |
|---|---|
| Beta | 0.729 |
| Beta Downside | 0.837 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.31% |
| CAGR/Max DD | 1.03 |
Description: OCS Oculis Holding Ordinary January 20, 2026
Oculis Holding AG (NASDAQ: OCS) is a Swiss clinical-stage biopharma focused on ophthalmic therapies, operating in Switzerland, Iceland and globally. Its lead pipeline includes OCS-01, a topical dexamethasone-optireach formulation now in Phase 3 for diabetic macular edema (DME); OCS-02, a topical biologic in Phase 2b for dry eye disease; and OCS-05, a neuroprotective agent targeting glaucoma, dry age-related macular degeneration, diabetic retinopathy and acute optic neuritis. The company, founded in 2017 and renamed from Oculis SA to Oculis Holding AG in March 2023, trades under the biotechnology GICS sub-industry.
Key industry and company metrics that add context: (1) The global DME market is projected to exceed $5 billion by 2028, driven by rising diabetes prevalence; (2) Oculis reported a cash balance of approximately CHF 30 million at the end of 2023, giving it a runway into 2025 under current burn rates; (3) Aging demographics in Europe and North America are expanding the addressable pool for glaucoma and AMD therapies, supporting long-term demand for OCS-05’s neuroprotective approach.
For a deeper dive into OCS’s financials and peer benchmarks, consider checking the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -104.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA 3.92 > 1.0 |
| NWC/Revenue: 23.3k% < 20% (prev 12.8k%; Δ 10.4k% < -1%) |
| CFO/TA -0.36 > 3% & CFO -60.0m > Net Income -104.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.7m) vs 12m ago 25.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.34% > 50% (prev 0.52%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: -117.8 > 6 (EBITDA TTM -103.0m / Interest Expense TTM 878.4k) |
Altman Z'' -15.00
| A: 0.70 (Total Current Assets 150.9m - Total Current Liabilities 33.7m) / Total Assets 167.8m |
| B: -2.15 (Retained Earnings -361.0m / Total Assets 167.8m) |
| C: -0.71 (EBIT TTM -103.5m / Avg Total Assets 146.7m) |
| D: -9.03 (Book Value of Equity -336.2m / Total Liabilities 37.2m) |
| Altman-Z'' Score: -16.65 = D |
Beneish M -3.91
| DSRI: 0.56 (Receivables 777.0k/1.78m, Revenue 504.0k/652.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.84 (AQ_t 0.08 / AQ_t-1 0.10) |
| SGI: 0.77 (Revenue 504.0k / 652.0k) |
| TATA: -0.26 (NI -104.1m - CFO -60.0m) / TA 167.8m) |
| Beneish M-Score: -3.91 (Cap -4..+1) = AAA |
What is the price of OCS shares?
As of February 08, 2026, the stock is trading at USD 28.48 with a total of 276,121 shares traded.
Over the past week, the price has changed by +0.11%, over one month by +36.27%, over three months by +46.73% and over the past year by +28.87%.
Over the past week, the price has changed by +0.11%, over one month by +36.27%, over three months by +46.73% and over the past year by +28.87%.
Is OCS a buy, sell or hold?
Oculis Holding Ordinary has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy OCS.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OCS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.8 | 60.7% |
| Analysts Target Price | 45.8 | 60.7% |
| ValueRay Target Price | 37.1 | 30.2% |
OCS Fundamental Data Overview February 03, 2026
Market Cap CHF = 1.28b (1.64b USD * 0.7768 USD.CHF)
P/S = 2079.1487
P/B = 9.5403
Revenue TTM = 504.0k CHF
EBIT TTM = -103.5m CHF
EBITDA TTM = -103.0m CHF
Long Term Debt = 2.47m CHF (from capitalLeaseObligations, last quarter)
Short Term Debt = 421.0k CHF (from shortTermDebt, last quarter)
Debt = 2.47m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = -44.0m CHF (from netDebt column, last quarter)
Enterprise Value = 1.23b CHF (1.28b + Debt 2.47m - CCE 46.4m)
Interest Coverage Ratio = -117.8 (Ebit TTM -103.5m / Interest Expense TTM 878.4k)
EV/FCF = -20.09x (Enterprise Value 1.23b / FCF TTM -61.4m)
FCF Yield = -4.98% (FCF TTM -61.4m / Enterprise Value 1.23b)
FCF Margin = -12.2k% (FCF TTM -61.4m / Revenue TTM 504.0k)
Net Margin = -20.7k% (Net Income TTM -104.1m / Revenue TTM 504.0k)
Gross Margin = unknown ((Revenue TTM 504.0k - Cost of Revenue TTM 14.9m) / Revenue TTM)
Tobins Q-Ratio = 7.35 (Enterprise Value 1.23b / Total Assets 167.8m)
Interest Expense / Debt = 8.21% (Interest Expense 202.4k / Debt 2.47m)
Taxrate = 21.0% (US default 21%)
NOPAT = -81.7m (EBIT -103.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.47 (Total Current Assets 150.9m / Total Current Liabilities 33.7m)
Debt / Equity = 0.02 (Debt 2.47m / totalStockholderEquity, last quarter 130.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -44.0m / EBITDA -103.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -44.0m / FCF TTM -61.4m)
Total Stockholder Equity = 127.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.95% (Net Income -104.1m / Total Assets 167.8m)
RoE = -81.69% (Net Income TTM -104.1m / Total Stockholder Equity 127.4m)
RoCE = -79.65% (EBIT -103.5m / Capital Employed (Equity 127.4m + L.T.Debt 2.47m))
RoIC = -64.14% (negative operating profit) (NOPAT -81.7m / Invested Capital 127.4m)
WACC = 8.60% (E(1.28b)/V(1.28b) * Re(8.60%) + D(2.47m)/V(1.28b) * Rd(8.21%) * (1-Tc(0.21)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.70%
Fair Price DCF = unknown (Cash Flow -61.4m)
EPS Correlation: -51.23 | EPS CAGR: -5.48% | SUE: 0.84 | # QB: 0
Revenue Correlation: -52.46 | Revenue CAGR: -11.67% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.83 | Chg30d=-0.010 | Revisions Net=-2 | Growth EPS=-1.6% | Growth Revenue=+572.9%
P/S = 2079.1487
P/B = 9.5403
Revenue TTM = 504.0k CHF
EBIT TTM = -103.5m CHF
EBITDA TTM = -103.0m CHF
Long Term Debt = 2.47m CHF (from capitalLeaseObligations, last quarter)
Short Term Debt = 421.0k CHF (from shortTermDebt, last quarter)
Debt = 2.47m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = -44.0m CHF (from netDebt column, last quarter)
Enterprise Value = 1.23b CHF (1.28b + Debt 2.47m - CCE 46.4m)
Interest Coverage Ratio = -117.8 (Ebit TTM -103.5m / Interest Expense TTM 878.4k)
EV/FCF = -20.09x (Enterprise Value 1.23b / FCF TTM -61.4m)
FCF Yield = -4.98% (FCF TTM -61.4m / Enterprise Value 1.23b)
FCF Margin = -12.2k% (FCF TTM -61.4m / Revenue TTM 504.0k)
Net Margin = -20.7k% (Net Income TTM -104.1m / Revenue TTM 504.0k)
Gross Margin = unknown ((Revenue TTM 504.0k - Cost of Revenue TTM 14.9m) / Revenue TTM)
Tobins Q-Ratio = 7.35 (Enterprise Value 1.23b / Total Assets 167.8m)
Interest Expense / Debt = 8.21% (Interest Expense 202.4k / Debt 2.47m)
Taxrate = 21.0% (US default 21%)
NOPAT = -81.7m (EBIT -103.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.47 (Total Current Assets 150.9m / Total Current Liabilities 33.7m)
Debt / Equity = 0.02 (Debt 2.47m / totalStockholderEquity, last quarter 130.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -44.0m / EBITDA -103.0m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -44.0m / FCF TTM -61.4m)
Total Stockholder Equity = 127.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -70.95% (Net Income -104.1m / Total Assets 167.8m)
RoE = -81.69% (Net Income TTM -104.1m / Total Stockholder Equity 127.4m)
RoCE = -79.65% (EBIT -103.5m / Capital Employed (Equity 127.4m + L.T.Debt 2.47m))
RoIC = -64.14% (negative operating profit) (NOPAT -81.7m / Invested Capital 127.4m)
WACC = 8.60% (E(1.28b)/V(1.28b) * Re(8.60%) + D(2.47m)/V(1.28b) * Rd(8.21%) * (1-Tc(0.21)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.70%
Fair Price DCF = unknown (Cash Flow -61.4m)
EPS Correlation: -51.23 | EPS CAGR: -5.48% | SUE: 0.84 | # QB: 0
Revenue Correlation: -52.46 | Revenue CAGR: -11.67% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.83 | Chg30d=-0.010 | Revisions Net=-2 | Growth EPS=-1.6% | Growth Revenue=+572.9%